A Phase II Trial of Paclitaxel in Patients with Advanced or Recurrent Adenocarcinoma of the Endometrium: A Gynecologic Oncology Group Study

摘要: Abstract Objective: To determine the efficacy and toxicity of paclitaxel in advanced or recurrent adenocarcinoma endometrium. Methods: Thirty patients with endometrial cancer measurable disease not previously treated chemotherapy were paclitaxel, 250 mg/m 2 , over 24 hr G-CSF, 5 mcg/kg/day, from Days to 12. The cycle was repeated every 21 days. Patients who had received previous pelvic radiation at an initial dose 200 . Twenty-eight evaluable for response, 29 toxicity. All Gynecologic Oncology Group performance status 0, 1, 2. Results: Complete responses observed 4 (14.3%) partial 6 (21.4%) a response rate 35.7%. Severe (grade 3 4) leukopenia thrombocytopenia seen 18 patients, respectively. Grade gastrointestinal 5, neurotoxicity 3, anemia 2, cardiac 1 patients. Alopecia reported 16 Conclusions: This schedule are active endometrium should be considered inclusion phase III trials.